These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23562150)

  • 1. A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder.
    Targum SD; Wedel PC; Robinson J; Daniel DG; Busner J; Bleicher LS; Rauh P; Barlow C
    J Psychiatr Res; 2013 Jul; 47(7):944-54. PubMed ID: 23562150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response.
    Kobak KA; Leuchter A; DeBrota D; Engelhardt N; Williams JB; Cook IA; Leon AC; Alpert J
    J Clin Psychopharmacol; 2010 Apr; 30(2):193-7. PubMed ID: 20520295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Audio-digital recordings used for independent confirmation of site-based MADRS interview scores.
    Targum SD; Pendergrass JC; Toner C; Asgharnejad M; Burch DJ
    Eur Neuropsychopharmacol; 2014 Nov; 24(11):1760-6. PubMed ID: 25239474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the Hamilton Depression Rating Scale and the Montgomery-Asberg Depression Rating Scale in depressed elderly: a meta-analysis.
    Heo M; Murphy CF; Meyers BS
    Am J Geriatr Psychiatry; 2007 Oct; 15(10):899-905. PubMed ID: 17911366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.
    Rush AJ; Trivedi MH; Carmody TJ; Ibrahim HM; Markowitz JC; Keitner GI; Kornstein SG; Arnow B; Klein DN; Manber R; Dunner DL; Gelenberg AJ; Kocsis JH; Nemeroff CB; Fawcett J; Thase ME; Russell JM; Jody DN; Borian FE; Keller MB
    Neuropsychopharmacology; 2005 Feb; 30(2):405-16. PubMed ID: 15578008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM
    J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Quick Inventory of Depressive Symptomatology-Self-report: a psychometric evaluation in patients with asthma and major depressive disorder.
    Brown ES; Murray M; Carmody TJ; Kennard BD; Hughes CW; Khan DA; Rush AJ
    Ann Allergy Asthma Immunol; 2008 May; 100(5):433-8. PubMed ID: 18517074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.
    Rush AJ; Bernstein IH; Trivedi MH; Carmody TJ; Wisniewski S; Mundt JC; Shores-Wilson K; Biggs MM; Woo A; Nierenberg AA; Fava M
    Biol Psychiatry; 2006 Mar; 59(6):493-501. PubMed ID: 16199008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical study results from a randomized controlled trial of cognitive behavioural guided self-help in patients with partially remitted depressive disorder.
    Schlögelhofer M; Willinger U; Wiesegger G; Eder H; Priesch M; Itzlinger U; Bailer U; Schosser A; Leisch F; Aschauer H
    Psychol Psychother; 2014 Jun; 87(2):178-90. PubMed ID: 23681925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
    Kornstein SG; Fava M; Jiang Q; Tourian KA
    Psychopharmacol Bull; 2009; 42(3):21-35. PubMed ID: 19752839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
    Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
    J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Categorical and dimensional stability of comorbid personality disorder symptoms in DSM-IV major depressive disorder: a prospective study.
    Melartin TK; Haukka J; Rytsälä HJ; Jylhä PJ; Isometsä ET
    J Clin Psychiatry; 2010 Mar; 71(3):287-95. PubMed ID: 20079331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.
    Trivedi MH; Rush AJ; Ibrahim HM; Carmody TJ; Biggs MM; Suppes T; Crismon ML; Shores-Wilson K; Toprac MG; Dennehy EB; Witte B; Kashner TM
    Psychol Med; 2004 Jan; 34(1):73-82. PubMed ID: 14971628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.